Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer
{{output}}
Background: Combining immune checkpoint inhibitors (ICI) with neoadjuvant chemotherapy (NACT) has been the standard of care for stage II and III triple negative breast cancer (TNBC) since 2021. For Luminal B/HER2(-) breast cancer... ...
